CCA
BIVV

Catalyst Capital Advisors’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Catalyst Capital Advisors’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-100,000
Closed -$5.71M – 521
2017
Q3 		$5.71M Hold
100,000
– – 0.25% 76
2017
Q2 		$6.02M Buy
+100,000
New +$5.69M 0.26% 68

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Catalyst Capital Advisors's BIVV Position: Q4 2017 in Review

Catalyst Capital Advisors sold out of Bioverativ Inc. Common Stock (BIVV) in Q4 2017, closing a stake of 100,000 shares — an estimated $5.71M sold.

Catalyst Capital Advisors first reported a position in BIVV in Q2 2017 and held it in 2 quarters. The position peaked at $6.02M in Q2 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Catalyst Capital Advisors reported no remaining Bioverativ Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Catalyst Capital Advisors sold 100,000 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $5.71M.
  • Catalyst Capital Advisors first reported a position in Bioverativ Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • Catalyst Capital Advisors's Bioverativ Inc. Common Stock position peaked at $6.02M in Q2 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Catalyst Capital Advisors's 13F filing for Q4 2017, filed 8 Feb 2018.